Integrated single-cell sequencing for the development of a GJA4-based precision immuno-prognostic model in melanoma

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-07-09 DOI:10.1016/j.tranon.2025.102450

Yantao Ding , Si Xie , Wenyang Nie , Yun Bai , Tianyu Yao , Yixiao Wang , Jiajie Chen , Bo Liang , Yi Zhou , Hui Cheng , Zaixing Wang , Shengxiu Liu

{"title":"Integrated single-cell sequencing for the development of a GJA4-based precision immuno-prognostic model in melanoma","authors":"Yantao Ding , Si Xie , Wenyang Nie , Yun Bai , Tianyu Yao , Yixiao Wang , Jiajie Chen , Bo Liang , Yi Zhou , Hui Cheng , Zaixing Wang , Shengxiu Liu","doi":"10.1016/j.tranon.2025.102450","DOIUrl":null,"url":null,"abstract":"<div><h3>Methods</h3><div>We conducted an analysis of RNA-seq and microarray data obtained from the TCGA and GEO databases, alongside single-cell RNA sequencing (scRNA-seq) data from glioma patients within the GEO repository. This comprehensive investigation, augmented by experimental studies, concentrated on exploring the interactions between tumor-associated endothelial cells (TECs) and tumors, as well as elucidating the molecular mechanisms involved.</div></div><div><h3>Results</h3><div>Single-cell sequencing analysis identified differentially expressed genes within tumor-associated endothelial cells. Further investigation highlighted GJA4 as a pivotal marker gene for a terminal subpopulation, with its expression linked to poor prognosis. Subsequent experiments were conducted to explore its underlying functional mechanisms.</div></div><div><h3>Conclusions</h3><div>GJA4 is highly expressed in melanoma patients, and its differential expression in tumor-associated endothelial cells influences melanoma proliferation and migration. GJA4-based risk models hold potential as predictive and therapeutic targets for personalized melanoma treatment.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"59 ","pages":"Article 102450"},"PeriodicalIF":5.0000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325001810","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Methods

We conducted an analysis of RNA-seq and microarray data obtained from the TCGA and GEO databases, alongside single-cell RNA sequencing (scRNA-seq) data from glioma patients within the GEO repository. This comprehensive investigation, augmented by experimental studies, concentrated on exploring the interactions between tumor-associated endothelial cells (TECs) and tumors, as well as elucidating the molecular mechanisms involved.

Results

Single-cell sequencing analysis identified differentially expressed genes within tumor-associated endothelial cells. Further investigation highlighted GJA4 as a pivotal marker gene for a terminal subpopulation, with its expression linked to poor prognosis. Subsequent experiments were conducted to explore its underlying functional mechanisms.

Conclusions

GJA4 is highly expressed in melanoma patients, and its differential expression in tumor-associated endothelial cells influences melanoma proliferation and migration. GJA4-based risk models hold potential as predictive and therapeutic targets for personalized melanoma treatment.

查看原文本刊更多论文

集成单细胞测序开发基于gja4的黑色素瘤精确免疫预后模型

方法我们分析了TCGA和GEO数据库中获得的RNA-seq和微阵列数据，以及GEO数据库中胶质瘤患者的单细胞RNA测序（scRNA-seq）数据。这项综合研究在实验研究的基础上，重点探讨了肿瘤相关内皮细胞（tec）与肿瘤之间的相互作用，并阐明了其中的分子机制。结果单细胞测序分析鉴定出肿瘤相关内皮细胞中差异表达的基因。进一步的研究表明GJA4是终末期亚群的关键标记基因，其表达与预后不良有关。随后进行了实验以探索其潜在的功能机制。结论sgja4在黑色素瘤患者中高表达，其在肿瘤相关内皮细胞中的差异表达影响黑色素瘤的增殖和迁移。基于gja4的风险模型有望成为个性化黑色素瘤治疗的预测和治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.